Parras

@BlupillAging Very happy to be part of the great project!

our products are based on real research. BLUPILL partners with VivoArchitect.com, an expert in longevity studies in mice. we design the formulations. they test them in vivo with scientific rigour, ethical standards, and full transparency. every compound is tested before it goes into a product. we share all data openly 💙

We really believed in this project from the very early stage and happy to keep a long-term collaboration!

@BlupillAging Gm raisers!

gm CT uphill workout is one of the best anti aging therapies ready to go up together?

My low cap picks for DeSci x Biotech 1. @TBDeSci $trackedbio CA: 7t1T28iMh5GsW8oTMx52x3u3M3hDbaY8psbL3rZ6BMrn It’s the official DeSci token of a real biotech company, Tracked Biotechnologies, focused on AI-driven automated phenotyping across flies, mice, and humans, with real products like TrackedFlyBox and active CRO services already in place. The bullish case comes from a successful ResearchHub replication study (which even got attention from Brian Armstrong), upcoming exposure at SynBioBeta 2026, a 10% revenue buyback mode. 2. @HairDAO_ $LAB CA: 3NVRZqJ43axJ7Jy8qtADxjFzgk8s2o5zaoLfQWRaAh7A It’s the lab token under HairDAO, a Solana-based DeSci project focused on hair regeneration R&D, combining real-world lab research with a decentralized science community. The bullish case comes from HairDAO already pushing forward with patents, tissue experiments, and a tissue bank, giving it real growth potential. It also sits right at the intersection of DeSci and the hair/peptide narrative, backed by actual experimental progress rather than just hype. 3. @BlupillAging $BLUPILL CA: drxLcknZZCeKaj1ABMUh4CeCGxYhB5mGihdGSUHdrug) The DeSci longevity token on @pumpdotscience, focused on using Sildenafil (Viagra) for lifespan research, led by a team of PhD scientists. Strong angle comes from real longevity use cases, scientist backing, and positioning within the DeSci + peptide narrative. Recently finished its initial launch phase, with a $DOCS holder airdrop coming and further experiments ahead. 4. @spark_sciences $SPARK CA: 2RDJ2BifKMPad67H7YfxM3JCVHPsjHeKpJGNwTxXpump A Solana-based DeSci platform focused on decentralized research funding, offering on-chain transparent grants, milestone-based unlocks, and public verification so anyone can fund and support real scientific work. The thesis is strong around its open, cross-disciplinary funding model, combined with on-chain governance and transparency. Recently gaining traction in DeSci discussions, with Realm DAO governance and active community initiatives. Worth watching their Telegram and upcoming grant activity. 5. @desciatoms $DATOMS CA: Hkbek42wiKQmVmGJYqfD6nbM3Lppyia7ZfY9k9ZioBLV A Solana-based DeSci analytics and visualization tool, offering market updates, 24h top gainers, and insights into total market cap and volume across the sector. The thesis is centered around data aggregation and visibility, helping fill the information gap in DeSci and acting as a useful dashboard for both long-term holders and researchers tracking the ecosystem. They’ve been consistently posting market reports and staying active within the DeSci community. Worth following on X for a clear overview of sector trends and emerging projects. 6. @rand_longevity $COQ CA: ozXG55AM1rqZS345kgDc21xCTaZKgzfXRXCF7Gydrug A Solana-based DeSci longevity token centered around CoQ10, a key mitochondrial compound linked to energy production and aging research. The angle is straightforward, it connects to a real supplement with established longevity relevance, fitting well into the broader DeSci + peptide + mitochondrial narrative. Recently showing up in longevity discussions, making it one to watch as DeSci health-related narratives continue to develop.

@BitmanTW @TBDeSci Lets go! Already 6 months since we started @BlupillAging project. We are working hard to make it!

we are back and the community knows it 🌕

@benjileibo @JillianCasalini @Space___Turtle @KristerKauppi @methblue_ @DeSciNews @AliG__89 @RyanBethencourt @eperlste @Grav_Amundsen @Sarah3oshi

we were born on @pumpdotscience, now turning science into product and brand back with the same mission 🚀 natural compound formulations for sexual longevity, backed by real science and open data. for men and women. if you followed us before, welcome back. if you're new, stick around. more science and updates coming💙

@BlupillAging 😅😅sure

some eggs matter more than others

@Rainmaker1973 @BlupillAging

A research links Viagra to a dramatically lower risk of Alzheimer’s. Recent observational research has revealed a striking association between sildenafil (the active ingredient in Viagra) and a substantially reduced risk of developing Alzheimer’s disease. In a large-scale analysis of U.S. insurance claims data covering more than 7.2 million people, researchers found that individuals who used sildenafil were 69% less likely to be diagnosed with Alzheimer’s disease over a six-year follow-up period compared to non-users. The study, which combined computational drug-repurposing methods with real-world patient data, suggests that sildenafil may offer neuroprotective benefits — possibly by improving blood flow to the brain, reducing harmful protein accumulation, and supporting neuron health. These effects extend well beyond the drug’s original purpose of treating erectile dysfunction and pulmonary hypertension. While the findings are highly promising, experts caution that this is an observational association, not proof of cause and effect. Confounding factors such as lifestyle or overall health could influence the results. To establish whether sildenafil can truly prevent or slow Alzheimer’s, rigorous randomized clinical trials are now needed. If confirmed, repurposing this safe, widely available, and relatively inexpensive medication could become a powerful new strategy in the fight against a disease that affects millions of families worldwide. [Fang, J., Zhang, P., Zhou, Y. et al. “Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease.” Nature Aging 1, 1175–1188 (2021). DOI: 10.1038/s43587-021-00138-z]

Fully funded through @pumpdotscience. Thanks to the token communities and developers: @BlupillAging @SMER28RAPA @trolpumpscience @NootropicsDAO_ @Big_Pharmai

Validating anti-aging therapies is still slow, expensive, and animal-intensive. Lifespan studies can take >2 yrs, cost over $200K, & require 100 mice. We developed a 4-month screening protocol that reduces animal use by 10x & costs by 20x. biorxiv.org/content/10.648… Your feedback is welcome before we move to peer review. Importantly, the study was fully funded through DeSci.

@BlupillAging 😂😂

what’s coming next? you basically get paid for having erections.

@BlupillAging nice update!